Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

Recruiting now · Not applicable

Conditions studied: Non-muscle Invasive Bladder Cancer (NMIBC)

In brief

The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.

Key facts

Study ID

NCT07187063

Run by

Lahey Clinic

People needed

56

Starts

2025-01-01

Expected to finish

2029-01-01

Last updated by the study team

2025-09-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• AUA high-risk bladder cancer1
• Received induction BCG or gemcitabine/docetaxel
• Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)

You may not qualify if…

• High-risk NMIBC within 3 years
• Prior induction intravesical therapy
• Variant histology
• Concurrent upper tract disease

Where it is running

• Lahey Hospital and Medical Center — Burlington, Massachusetts, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.